CA2825309C - Pyridostigmine for the treatment of obstructive sleep apnea - Google Patents

Pyridostigmine for the treatment of obstructive sleep apnea Download PDF

Info

Publication number
CA2825309C
CA2825309C CA2825309A CA2825309A CA2825309C CA 2825309 C CA2825309 C CA 2825309C CA 2825309 A CA2825309 A CA 2825309A CA 2825309 A CA2825309 A CA 2825309A CA 2825309 C CA2825309 C CA 2825309C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
sleep
pyridostigmine
subject
osa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2825309A
Other languages
English (en)
French (fr)
Other versions
CA2825309A1 (en
Inventor
Jian-Qiang Fan
Original Assignee
PFANTASTIC MEDICAL RESEARCH INSTITUTE LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFANTASTIC MEDICAL RESEARCH INSTITUTE LLC filed Critical PFANTASTIC MEDICAL RESEARCH INSTITUTE LLC
Publication of CA2825309A1 publication Critical patent/CA2825309A1/en
Application granted granted Critical
Publication of CA2825309C publication Critical patent/CA2825309C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices ; Anti-rape devices
    • A61F5/56—Devices for preventing snoring
    • A61F5/566—Intra-oral devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/0057—Pumps therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Nursing (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2825309A 2011-01-28 2012-01-27 Pyridostigmine for the treatment of obstructive sleep apnea Active CA2825309C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161437272P 2011-01-28 2011-01-28
US61/437,272 2011-01-28
PCT/US2012/022825 WO2012103398A2 (en) 2011-01-28 2012-01-27 Methods for treating obstructive sleep apnea

Publications (2)

Publication Number Publication Date
CA2825309A1 CA2825309A1 (en) 2012-08-02
CA2825309C true CA2825309C (en) 2019-10-01

Family

ID=46577943

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2825309A Active CA2825309C (en) 2011-01-28 2012-01-27 Pyridostigmine for the treatment of obstructive sleep apnea

Country Status (6)

Country Link
US (2) US8753327B2 (enExample)
EP (1) EP2672972B1 (enExample)
JP (2) JP2014503593A (enExample)
CN (2) CN103458899A (enExample)
CA (1) CA2825309C (enExample)
WO (1) WO2012103398A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2672972B1 (en) * 2011-01-28 2020-11-04 Pfantastic Medical Research Institute, LLC Methods for treating obstructive sleep apnea
JP2017506929A (ja) * 2014-03-03 2017-03-16 スリープ イノベイションズ プロプライアタリー リミティド 睡眠時無呼吸治療の装置及び方法
WO2016014229A1 (en) 2014-07-25 2016-01-28 Mendelowitz David Oxytocin improves treatment of obstructive sleep apnea
JP6480598B2 (ja) 2015-04-02 2019-03-13 ヒル−ロム サービシーズ プライヴェート リミテッド 呼吸装置用マニホールド
CN110198688B (zh) * 2016-12-23 2022-06-24 皇家飞利浦有限公司 用于处置至少两个用户间的打鼾的系统
GEAP202416602A (en) * 2017-04-28 2024-10-10 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
SI3746126T1 (sl) 2018-01-30 2025-01-31 Apnimed, Inc. (Delaware) Postopki in sestavki za zdravljenje spalne apneje ali preprostega smrčanja
ES2861153T3 (es) * 2018-06-18 2021-10-05 Composiciones de liberación prolongada que comprenden piridostigmina
WO2020038900A1 (en) * 2018-08-24 2020-02-27 Koninklijke Philips N.V. Providing sleep therapy with a pressure therapy system
EA202192202A1 (ru) 2019-02-08 2021-11-03 Дзе Брихэм Энд Уимен'З Хоспитал, Инк. Способы и композиции для лечения синдрома обструктивного апноэ, возникающего во сне
US11266837B2 (en) 2019-03-06 2022-03-08 Medtronic Xomed, Inc. Position sensitive lingual muscle simulation system for obstructive sleep apnea
CN114504643B (zh) * 2021-12-24 2024-03-26 北京大学第一医院 抗IgE抗体在用于治疗OSAS中的应用
CN120390613A (zh) * 2022-12-28 2025-07-29 西川株式会社 健康风险判定系统、自律神经判定系统、生活改善系统、睡姿判定系统、睡姿判定程序、磨牙检测系统及磨牙检测程序

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2247662B (en) 1990-08-31 1994-11-02 Instance Ltd David J Labels and manufacture thereof
SE9504537D0 (sv) 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
WO2005016327A2 (en) * 2003-08-13 2005-02-24 Janssen Pharmaceutica, N.V. Treatment of sleep disorders with cholinesterase inhibitors
CA2622721A1 (en) * 2005-09-16 2007-03-22 Cereuscience Ab Method and means of preventing and treating sleep disordered breathing
US20080066739A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US7984714B2 (en) * 2006-09-29 2011-07-26 Nellcor Puritan Bennett Llc Managing obstructive sleep apnea and/or snoring using local time released agents
EP2672972B1 (en) * 2011-01-28 2020-11-04 Pfantastic Medical Research Institute, LLC Methods for treating obstructive sleep apnea

Also Published As

Publication number Publication date
WO2012103398A2 (en) 2012-08-02
CA2825309A1 (en) 2012-08-02
JP2017095485A (ja) 2017-06-01
EP2672972A2 (en) 2013-12-18
WO2012103398A9 (en) 2012-09-27
US20140238412A1 (en) 2014-08-28
JP6342525B2 (ja) 2018-06-13
CN107007602A (zh) 2017-08-04
CN103458899A (zh) 2013-12-18
EP2672972B1 (en) 2020-11-04
US8753327B2 (en) 2014-06-17
JP2014503593A (ja) 2014-02-13
US20120197235A1 (en) 2012-08-02
EP2672972A4 (en) 2014-09-10
US9295670B2 (en) 2016-03-29

Similar Documents

Publication Publication Date Title
CA2825309C (en) Pyridostigmine for the treatment of obstructive sleep apnea
Jin et al. Minimizing perioperative adverse events in the elderly
Oksenberg Treating obstructive sleep apnea improves essential hypertension and quality of life
CN110799181A (zh) 用于治疗睡眠呼吸暂停的方法和组合物
JP5712452B2 (ja) 診断された呼吸疾患を有する患者もしくは診断未確定の呼吸疾患を有する患者におけるオピオイド鎮痛薬の投与に関連する危険性を減少するための方法および組成
JP7705348B2 (ja) 睡眠時無呼吸を治療するための方法および組成物
CN100558358C (zh) 唑尼沙胺在制备用于治疗或预防阻塞性睡眠呼吸暂停的药物中的应用
CN1278731A (zh) 米氮平用于治疗睡眠性呼吸暂停的用途
HK1241728A1 (en) Methods for treating obstructive sleep apnea
Pillar et al. Amelioration of Sleep Apnea by Salicylate-induced Hyperventilation1, 2
Paunikar et al. A Textbook of Pharmacology-III
KR20250000641A (ko) 수면장애 및/또는 수면장애 관련 질환을 예방, 개선 또는 치료하는 방법
HK40109449A (zh) 慢性咳嗽、呼吸急促和呼吸困难的治疗
HK40109451A (zh) 慢性咳嗽、呼吸急促和呼吸困难的治疗
HK40109450A (zh) 慢性咳嗽、呼吸急促和呼吸困难的治疗
WO2025111597A1 (en) A treatment for patients with mood disorders using n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine or a pharmaceutically acceptable salt thereof
HK40109448A (zh) 慢性咳嗽、呼吸急促和呼吸困难的治疗
Dobbin et al. Obstructive sleep apnea: recognition and management considerations for the aged patient
CN115998735A (zh) 一种伏乌碱在制备镇痛药物中的应用
HK40045293B (zh) 慢性咳嗽、呼吸急促和呼吸困难的治疗
Trounce Drugs in Current Use
Paul Comparison of Tramadol and Pethidine for Control of Shivering in Regional Anaesthesia
CZ300781B6 (cs) Použití R-(+)-alfa-(2,3-dimethoxyfenyl)-1-[2-(4-fluorfenyl)ethyl]-4-piperidinmethanolu pro lécení poruch spánku
Milani Levocloperastine: A Review on pharmacodynamics, clinical efficacy, tolerability and safety in the treatment of chronic cough
FARIDI et al. Postoperative analgesia: a comparison of sublingual buprenorphine and intramuscular morphine for pain relief after abdominal hysterectomy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170124

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250123

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250123